Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...

Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

AstraZeneca and Daiichi Sankyo’s Datroway has become the first cancer drug to show an overall survival benefit against chemotherapy for certain patients with a particularly aggressive form of breast ...

Cancer is always scary, but few diagnoses carry as much weight as triple negative breast cancer (TNBC). Accounting for 10 to ...

A pre-specified interim analysis showed dual primary endpoint success, with improved PFS and OS versus physician’s-choice chemotherapy in taxane-progressed advanced TNBC. BL-B01D1-307 was a randomized ...

Hearing the words “triple-negative breast cancer” (TNBC) can be overwhelming. It’s a diagnosis that sounds heavy — not just because breast cancer itself is frightening, but because this particular ...

Please provide your email address to receive an email when new articles are posted on . First-line sacituzumab govitecan significantly improved PFS for metastatic triple-negative breast cancer subset ...

Breakthrough combinations: Pairing immunotherapy with targeted antibody-drug conjugates is showing improved survival rates for TNBC patients. Why TNBC is tough: Lacking key hormone and HER2 markers, ...

KILLEEN, Texas — When Shewanna Strickland went in for a routine mammogram in April 2024, just after turning 50, she never imagined the journey that lay ahead. What started as a concerning spot on her ...

KILLEEN, Texas — When Shewanna Strickland went in for a routine mammogram in April 2024, just after turning 50, she never imagined the journey that lay ahead. What started as a concerning spot on her ...